Adverse Effects of Ivermectin Used in Egypt During COVID-19

• Sponsor: Menoufia University (Other)
• Overall Status: Enrolling by invitation
• CT.gov ID: NCT04747678
• Collaborator: (none)
• Enrollment: 200
• Location: 1
• Anticipated Duration (Days): 26
• Patients Per Site Per Month: 234.1

Study Details

Study Description

Brief Summary

retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt

Condition or Disease	Intervention/Treatment	Phase
Covid19; Ivermectin Poisoning; Drug Toxicity; Drug Side Effect	Drug: Ivermectin

Detailed Description

ivermectin was used in Egypt during the pandemic of covid-19 and it was registered in the MOH protocol that has been published in November 2020 the study will document the adverse effects of many patients used ivermectin as aprophylaxis and as a treatment with multiple dose regimens

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 200 participants
• Observational Model: Case-Crossover
• Time Perspective: Cross-Sectional
• Official Title: Tolerability and Adverse Effects of Using Multiple Doses of Ivermectin in Egypt During Covid 19 Pandemic
• Anticipated Study Start Date: Feb 3, 2021
• Anticipated Primary Completion Date: Feb 28, 2021
• Anticipated Study Completion Date: Mar 1, 2021

Outcome Measures

Primary Outcome Measures

1. all adverse effects will be collected from people used Ivermectin in between September 2020 to December 2020 [the data will be collected from February 2021 to march 2021]

   all data will be collected from retrospective manner as a retrospective study

Secondary Outcome Measures

1. all data will be arranged according to time and dose manner [February to match 2021]

   data for each dose will be identified together

Eligibility Criteria

Criteria

• Ages Eligible for Study: 16 Years to 80 Years
• Sexes Eligible for Study: All

Inclusion Criteria:

• all people used ivermectin as a treatment or as a prophylactic in covid 19 pandemic in egypt with explained dose

Exclusion Criteria:

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ahmed Mansour	Shibīn Al Kawm	Menoufia	Egypt	24222

Sponsors and Collaborators

• Menoufia University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: ahmed mohamed esmat fahim mansour, Principal Investigator, Menoufia University
• ClinicalTrials.gov Identifier: NCT04747678
• Other Study ID Numbers: ahmed19782020
• First Posted: Feb 10, 2021
• Last Update Posted: Feb 10, 2021
• Last Verified: Feb 1, 2021

• Additional relevant MeSH terms: COVID-19; Poisoning; Drug-Related Side Effects and Adverse Reactions; Ivermectin

Study Results

No Results Posted as of Feb 10, 2021